Brokmann Friederike, Simonek Paul, Rosenbaum Christoph
Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Straße 3, 17489 Greifswald, Germany.
Pharmaceutics. 2024 Aug 1;16(8):1021. doi: 10.3390/pharmaceutics16081021.
The increasing prevalence of esophageal disease highlights the clinical relevance of novel, long-lasting mucoadhesive oral dosage forms. The EsoCap device enables targeted local application of films in the esophagus. Biorelevant test systems such as EsoPeriDiss are essential for early formulation development. To this end, the developed and already described release model for simulating the esophagus is being further developed for its potential for biorelevant mapping of the application site through complete tempering and investigation of biorelevant release media. Particularly viscous saliva formulations led to an extension of the retention time. In addition, possible formulation strategies for increasing the retention time of esophageal applied films are being evaluated, such as different film thicknesses, polymer grades and the influence of different active ingredient properties on the retention time. For highly soluble active ingredients, the film thickness represents an option for extending the retention time, while for less soluble substances, the choice of polymer grade may be of particular interest.
食管疾病患病率的不断上升凸显了新型长效粘膜粘附口服剂型的临床相关性。EsoCap装置能够将薄膜靶向局部应用于食管。诸如EsoPeriDiss等生物相关测试系统对于早期制剂开发至关重要。为此，已开发并已描述的用于模拟食管的释放模型正在进一步开发，以通过完全调温和研究生物相关释放介质来实现对应用部位进行生物相关映射的潜力。特别粘稠的唾液制剂导致保留时间延长。此外，正在评估增加食管应用薄膜保留时间的可能制剂策略，例如不同的薄膜厚度、聚合物等级以及不同活性成分特性对保留时间的影响。对于高溶解性活性成分，薄膜厚度是延长保留时间的一种选择，而对于低溶解性物质，聚合物等级的选择可能特别重要。
